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Open access under CC BY license.Complement is a key component of immune defence
against infection; it potently drives inflammation at sites
of pathology and is essential for killing of pathogens.
Genetic linkage of common complement polymor-
phisms to disease has advanced the concept that subtle
changes in complement activity significantly affect dis-
ease risk. Functional analyses of disease-linked polymor-
phic variants demonstrate that, although individual
polymorphisms cause only small changes in activity,
when combined, the aggregate effects are large. The
inherited set of common variants, the complotype, thus
has a major impact on susceptibility to inflammatory
and infectious diseases. Assessing the complotype of an
individual will aid prediction of disease risk and inform
intervention to reduce or eliminate risk.
Complement system
Complement is a major component of innate immunity and
offers a first line of defence against infection by triggering
inflammatory responses to alert the immune system to
impending danger. Complement plays crucial roles in
targeting and killing microbes and infected cells, flagging
them for phagocytic clearance and punching holes through
cell membranes to cause lysis. Its role extends beyond
fighting infection; it is also required for efficient clearance
of apoptotic cells and immune complexes as well as, per-
haps more surprisingly, modulating adaptive immune
responses. Complement is a proteolytic cascade, triggered
via three activation routes, the classical pathway (CP), the
lectin pathway (LP) and alternative pathway (AP); togeth-
er, these recognise almost any potential target (reviewed
in [1]).
During the past decade, several studies have associated
genetic variations in complement components and regula-
tors with various chronic and infectious diseases. The
recent functional characterisation of these complement
protein variants has provided important insights into
the pathogenic mechanisms involved in complement-relat-
ed disorders. Here, we review evidence linking complement
polymorphisms with disease, and discuss recent research
that identifies the functional mechanisms behind genetic
linkages in the complement AP. We introduce the concept
of the ‘complotype’, which represents the pattern of genetic
variants in complement genes inherited by an individual,
which alters risk for both inflammatory disorders andCorresponding author: Harris, C.L. (harriscl@cardiff.ac.uk)
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suggests that the complotype also extends beyond the AP
to include both activating and control proteins from other
complement pathways. A detailed understanding of the
complotype will aid prediction of disease susceptibility and
assessment of current disease status, and inform decisions
on therapeutic interventions.
Key role of AP convertase
The key steps during complement activation involve
formation of labile enzymatic complexes named C3-
convertases [C3bBb (AP); C4b2a (CP and LP)], which
cleave C3 to generate C3b. The AP C3 convertase is crucial
for efficient complement activation, regardless of the initial
trigger, because it amplifies the response and is intrinsi-
cally active, in contrast to the CP and LP C3-convertases
for which activation is triggered by immune complexes and
bacterial mannose groups respectively (reviewed in [2])
(Box 1). Continuous production of activated C3, either
C3(H2O) produced by spontaneous hydrolysis of the inter-
nal thioester, or C3b generated by convertases or other
plasma proteases in plasma, is known as ‘tickover’ [3]. This
ensures low-level generation of AP convertase, necessary
for depositing C3b onto surfaces (Box 1). Thus, the AP is
‘primed’ for immediate activation and amplification, lead-
ing to C3b deposition on the target pathogen and ‘foreign’
surface. Tickover activation is stringently controlled by
factor H (fH), which, in collaboration with the plasma
serine protease factor I (fI), inactivates C3b and C3 con-
vertases [4,5]. fH is an abundant plasma protein (0.2–0.5 g/l)
with an elongated structure presenting several binding sites
for C3b and glycosaminoglycans (GAGs) along its length.
The GAG-binding domains are key for protection of self
tissues because they locate fH to cell membranes where it
dissociates deposited AP convertases and, together with fI,
inactivates C3b. FH is a member of a gene family that
includes five homologous fH-related proteins (FHR1–5)
(reviewed in [5]). These may also have AP regulatory roles
analogous to fH; alternatively, they may act as competitors
to inhibit fH regulation [6]. Self tissues are also protected by
membrane-bound proteins that restrict complement activa-
tion by either acting as cofactor for proteolytic inactivation of
C3b by fI or by accelerating convertase dissociation (Box 1)
(reviewed in [7,8]). Thus, in health, spontaneous activa-
tion of C3 in plasma is kept at a low level and further
complement activation and C3b deposition is restricted to
targets lacking surface regulators. Trends in Immunology, October 2012, Vol. 33, No. 10 513
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In health, complement is in homeostatic balance. Tickover
confers the capacity for rapid activation and amplification
on pathogens, which is essential for efficient clearance but
is risky in the sense that any disturbance in homeostasis
can provoke damage to self. Dysregulation of the central
components of the AP amplification loop, C3, factor B (fB),
factor D (fD), or the control proteins, fH and fI, might
therefore be predicted to affect plasma AP activity, thereby
affecting risk of acute or chronic inflammation and
disease.
Common polymorphisms in AP protein genes, including
those encoding C3, fB and fH, are associated with disease
risk (Box 2), although the underlying mechanisms have
been unknown. The best example of a disease strongly
linked to AP polymorphisms is age-related macular degen-
eration (AMD). End-stage (blinding) AMD affects 2% of
those aged over 50 years, with the incidence rising steeply
with age and approaching 20% in those over 85 years.
Annual cost to the UK economy exceeds £5 billion [9].
Retinal drusen, the hallmark of AMD, is known to contain
complement proteins, but little was made of this until 2005
when several papers linked the common H1 haplotype of
the fH gene (CFH), including the fHY402H polymorphism
(rs1061170), with AMD. Two copies of the risk haplotype
increased odds of developing AMD seven fold [10–12]. A
second CFH haplotype, H2, was protective for AMD; this
haplotype includes the fHV62I variant [rs800292; odds ratio
(OR) 0.54] [13]. The H4 haplotype that carries a deletion of
the genes encoding the FHR proteins 1 and 3 (CFHR1,
CFHR3), is protective for AMD (OR 0.48) [14] and this
deletion is common in Caucasians (null allele frequency
20%). A common allelic variation in the CFHR1 gene is the
FHR1*A variant that differs from FHR1*B by three amino
acids [15]. CFHR1*A is risk for AMD (OR 2.08) and in
strong linkage disequilibrium (LD) with the CFH-402H
allele [16]. AMD associations are also reported for variants
in genes encoding key AP proteins that either promote
or control the AP amplification loop (Box 1). These
include fB (fBR32Q, rs641153; protective, OR 0.32) [17],
and C3 (C3R102G, rs2230199; risk, OR:2.6) [18]; a recent
targeted genotyping approach identified a single nucleotideBox 1. Complement activation and regulation
Continuous, low level activation of C3 in plasma occurs through tickover;
either spontaneous hydrolysis of the internal C3 thioester generates a
C3b-like molecule, C3(H2O), or cleavage of C3 by plasma proteases
generates C3b. These nascent, active molecules bind fB to form an AP
convertase that cleaves C3 to C3b. In the AP amplification loop, C3b,
either surface-bound or in the fluid phase, binds fB in a Mg2+-dependent
manner and presents fB for cleavage by the plasma protease factor D
(fD). The enzymatic fragment, Bb, remains attached to C3b and cleaves
more C3 to C3b. Each C3 convertase can cleave many C3 molecules into
C3b; thus, the AP amplification loop is a self-perpetuating pathway
driving complement activation (Figure I). The C3bBb enzyme is naturally
labile because Bb spontaneously dissociates from C3b with a half-life of
about 90 s at 37 8C; however, binding of properdin (P) into the complex
stabilises the enzyme and extends its half-life more than 10-fold.
Initiation of the CP and LP involves recognition of the target either
through C1q binding target-bound antibody (CP) or MBL binding
pathogen-specific sugar groups (LP). The associated protease units
514polymorphism (SNP) just 30 of the gene encoding fI (CFI)
that is associated with reduced AMD risk [19].
Dense deposit disease (DDD) is a rare cause of renal
failure associated with copious complement deposition in
the kidney and systemic activation of AP components
(reviewed in [20]). Clinically, DDD is linked to AMD –
most DDD patients develop eye changes typical of AMD at
a comparatively young age. The CFH haplotypes associat-
ed with increased (H1 including rs1061170; fHY402H) and
decreased (H2, including rs800292; fHV62I) risk of AMD
conferred similar effects on DDD risk [21]. C3 polymor-
phisms (C3R102G and C3P314L) also increase risk of DDD
and, importantly, DDD risk increases dramatically when
two or more risk alleles in fH and C3 are present in an
individual [22].
Atypical haemolytic uremic syndrome (aHUS) is a rare,
life-threatening, disease characterised by a triad of throm-
bocytopenia, microangiopathic haemolytic anaemia and
acute renal failure with abundant renal complement
deposits [20]. Of the AP polymorphisms linked to AMD
and DDD, only fHV62I influences risk of aHUS [21]. The
fHY402H and C3R102G, variants, which are risk factors in
AMD/DDD, do not affect aHUS, and the CFHR1/CFHR3
deletion that is protective in AMD, is risk for aHUS,
because lack of FHR1 is strongly associated with serum
anti-fH autoantibodies [15]. Two other common haplotypes
in CFH and MCP are strong aHUS risk factors [23,24].
Over half of aHUS patients have point mutations in AP
proteins, commonly in fH, these are clustered in the car-
boxy terminus and disrupt the capacity of fH to bind to
surfaces [25,26]. Other complement protein mutations also
associate with aHUS risk, including gain-of-function muta-
tions in fB and C3 [27,28]. These mutations cause AP
dysregulation by either enhancing convertase formation/
stability or disrupting convertase regulation (reviewed in
[29]); for each, penetrance is incomplete and co-inheritance
of risk-conferring polymorphisms in the same or different
AP proteins markedly increases odds of developing disease
[24,30].
The fact that many of the variants affecting susceptibil-
ity to AMD/DDD have no effect on risk of aHUS and vice
versa implies that these diseases of complement dysregu-
lation have different underlying mechanisms [26,29].(C1s and mannan-binding lectin-associated serine protease 2 (MASP-
2) respectively) then cleave C4 to C4b. Surface-bound C4b expresses a
binding site for C2, leading to formation of the proenzyme C4b2.
Cleavage of C2 by MASP-2 or C1s generates the active C3 convertase
C4b2a. The AP amplifies the effects of activation of the CP and LP by
generating AP C3 convertase from any C3b generated through these
pathways. The activation pathway C3 convertases all cause C3b to
shower down onto the target cell surface in the vicinity of the
convertase, where it binds covalently to other C3b, the convertase, or
other membrane structures in close proximity: C3b that binds the C3
convertase creates a new enzyme, the C5 convertase, C3bBbC3b or
C4b2a3b, which cleaves C5 to C5b and C5a. C5a is a highly
proinflammatory polypeptide which diffuses from the target surface
to recruit other immune effectors, whereas C5b is the first structural
building block of the lytic pore, the MAC. C5b sequentially binds the
terminal pathway components, C6–C9, to assemble the macromole-
cular complex which forms holes through the membrane.
Self tissues are protected from accidental complement attack by
proteins present in plasma and on cell membranes. These proteins
are fH (AP-specific), C4b-binding protein (C4 bp; CP-specific), mem-
brane cofactor protein (MCP, CD46), decay accelerating factor (DAF,
CD55) and CR1 (CD35). These proteins restrict complement activation
on self cells by either catalyzing proteolytic inactivation of C3b/C4b by
fI (MCP, CR1, fH, C4 bp) or accelerating convertase dissociation (DAF,
CR1, fH, C4 bp) [8].
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Figure I. Central role of AP convertase in complement activation. Complement tickover occurs through hydrolysis of the C3 thioester, or cleavage of C3 to C3b by
plasma proteases. Fluid phase production of either molecule results in formation of the AP C3 convertase, C3bBb, and production of further C3b which either binds a
surface or remains fluid phase. Each newly produced C3b can in turn form a convertase, which cleaves C3, resulting in exponential production of C3b. This self-
propagation, referred to as the ‘amplification loop’ and indicated here in red, is responsible for amplifying a small trigger to yield large responses. C3b formed through
any activation pathway feeds into the amplification loop. Binding of C3b to C3 convertase creates C5 convertase; cleavage of C5 and generation of C5b marks the start of
the terminal pathway. C6 and C7 bind C5b to form C5b67, which is released from convertase, binds membrane and incorporates C8 and multiple C9 molecules to form
the MAC. Self tissues are protected from accidental complement damage by regulatory proteins present in plasma and on membranes, indicated by maroon boxes.
Note the abundance of regulators which control the amplification loop and C3 convertases.
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Box 2. Discovery and genotyping of AP complement
polymorphisms
It has long been recognised that C3, fB and fH are polymorphic. The
C3 R102G polymorphism was initially described at the protein level in
1967 as the C3S and C3F alleles; separated using prolonged agarose
gel electrophoresis of fresh serum [77]. Similarly, the commonest
factor B alleles BfS and BfF (now the R32W/Q polymorphism) were
identified in 1972 using immunofixation after agarose gel electro-
phoresis of fresh serum [78]. Over a decade later, the common fH
alleles FH*1 and FH*2 (now the Y402H polymorphism) were identified
by isoelectric focusing in human serum after neuraminidase treat-
ment under completely denaturing conditions [79].
During the 1990s, the knowledge, resources, and technologies
emanating from the Human Genome Project resulted in the
identification of most genetic variations in the human genome with
frequencies >5%, including those in the AP complement genes. This
understanding of human genetic variability resulted in an explosion
of genetic studies, including genome wide association studies and
candidate gene approaches, that have revealed association of
complement genetic variations with disease and uncovered the
important genotype–phenotype correlations discussed in this review.
Current methods for genotyping genetic variations in comple-
ment components do not differ from genotyping of any other gene.
Genomic DNA is extracted from saliva, oral cavity mucosa or blood
cells and analysed using a wide range of platforms based on DNA
sequencing, DNA hybridization or mass spectrometry technologies.
Information related to genetic variations in complement genes can
be found in several human genome databases in the public domain,
including, the dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/),
the 1000 Genomes (http://www.1000genomes.org/) and the Exome
Variant Server (http://evs.gs.washington.edu/EVS/).
Review Trends in Immunology October 2012, Vol. 33, No. 10The current understanding is that aHUS occurs when the
capacity to prevent inappropriate AP activation on cell
surfaces is impaired, whereas AMD/DDD occurs when
AP fluid-phase regulation is impaired. Several groups have
used plasma complement proteins as biomarkers in AMDC3b
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Figure 1. Functional effects of complement protein polymorphisms. C3b generated by tic
the alternative pathway (AP) pro-convertase (C3bB). Factor D (fD) cleaves fB in the pro-
membranes, captures fB and builds more convertase (the AP amplification loop). The p
binds C3b in the convertase, displacing Bb to inactivate the convertase. fH bound to C3
iC3b. Complement polymorphisms affect AP activation/regulation in different ways (re
binds better so makes more pro-convertase, more convertase and more AP activation (s
C3b102G binds fH less strongly (weaker binding illustrated by broken red arrow), leading
SCR1, green) also affects C3b-fH binding; fH62I binds C3b more strongly (unbroken ar
activation. These three AP polymorphisms, influencing AP activity in different ways, col
also affect activity; for example, the AMD-associated fHY402H polymorphism (in SCR7,
convertase regulation.
516for early detection, disease monitoring or to guide inter-
vention; elevated plasma levels of activation fragments
C3a, C3dg, C5a, and Bb, terminal complement complex
(TCC), and fD are potential AMD biomarkers and can
similarly be used to anticipate aHUS recurrences [31–33].
Identifying functional consequences of complement
AP polymorphisms
Despite dramatic effects on disease susceptibility, the
underlying mechanisms by which common polymorphisms
in AP proteins alter disease risk have remained unclear.
The situation is further complicated by the fact that the
CFH, CFHR3 and CFHR1 genes comprise a major suscep-
tibility locus including one haplotype conferring increased
risk (H1) and two that protect (H2, H4) from AMD.
Although fH402H, fH62V and DCFHR3–CFHR1 have been
implicated as the responsible genetic variants within re-
spective haplotypes, any of the polymorphisms in that
haplotype could be functionally responsible, making it
difficult to pinpoint the culprit. To address this issue, a
biochemical approach has been used to identify how poly-
morphisms predispose to disease. AP protein variants were
purified to homogeneity from healthy, homozygous donors
and the effects of these single amino acid changes on AP
activity tested. The AMD-linked polymorphism in fB
(fBR32Q) is in the Ba domain that is released during forma-
tion of the active enzyme C3bBb. Nevertheless, the risk
variant, fB32R, was more lytic in complement functional
assays due to higher affinity for C3b compared to fB32Q,
which gives rise to enhanced formation of proenzyme,
C3bB, and increased formation of active convertase
(Figure 1a) [34]. The fHV62I polymorphism altered the
capacity of fH to regulate C3b; fH62I bound better toRegulation
C3f
fI
H
fH62IfH62V
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C3f
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kover routes binds surfaces through its thioester. C3b captures factor B (fB) to form
convertase to yield C3 convertase (C3bBb); this cleaves more C3 to C3b that binds
lasma AP regulator factor H (fH) comprises 20 short consensus repeats (SCRs); fH
b is also a cofactor for cleavage of C3b by factor I (fI) to yield the inactive product
d arrows). The fBR32Q modulates fB affinity for C3b in convertase formation; fBR32
tronger binding illustrated by solid red arrow). C3R102G affects affinity of C3b for fH;
 to less efficient C3b inactivation by fI, and thus drives more AP activation. fHV62I (in
row) so better regulates the convertase, facilitates C3b cleavage and inhibits AP
laborate to set AP activating capacity. Other disease-associated AP polymorphisms
 blue) probably alters capacity of fH to bind surfaces in the eye, influencing local
Review Trends in Immunology October 2012, Vol. 33, No. 10C3b, resulting in enhanced cofactor activity and increased
formation of iC3b (Figure 1b) [35,36]. Association of the
common C3 polymorphism (C3S/F; C3R102G) with many
diseases, including AMD, has been recognised for decades
but the molecular basis of disease association has been
enigmatic. The purified AMD risk variant, C3102G, bound
fH less strongly than C3102R and was less efficiently inac-
tivated, thereby increasing AP activity (Figure 1c) [37]. All
three polymorphisms directly influence the AP convertase,
although each alone had a relatively small effect, for
example, the KD of the fH62V variant for C3b binding
was 1.3 mM, and that of the fH62I variant was 1.0 mM.
When combined, the functional effect of the variants was
greatly enhanced; this is because all three proteins pro-
mote or control the amplification loop, which is key for
amplifying small triggers to give massive downstream
effects (Box 1). In assays that simultaneously interrogated
the effects of polymorphisms in all three proteins on con-
vertase activity, AMD risk variants together were sixfold
more active than the combined AMD protective variants
[37]. Even in an AP haemolytic assay (AH50), a clinical test
which does not fully interrogate fH function, the combina-
tion of three AMD-risk variants yielded whole serum with
twice the complement haemolytic activity of serum con-
taining protective variants. This dramatic variability in AP
activity will inevitably influence tissue damage and inflam-
mation wherever complement is activated. In support of
these data, combined inheritance of DDD risk polymor-
phisms in fH and C3 was associated with higher AP
activity in genotyped healthy controls [22].
The mechanism by which the fHY402H polymorphism
affects disease risk is unresolved, but there is no evidence
to suggest that it is due to altered AP convertase regulation
(Figure 1d). Differential binding to C-reactive protein
(CRP), an acute phase reactant that binds to damaged
cells has been described [38,39]. Other studies suggest
differential binding to heparin and other polyanionic
ligands [40–42]; indeed, ex vivo binding studies in AMD
retina have shown preferential binding of fH402Y to Bruch’s
membrane that is dependent on sulfated GAGs [43]. Re-
cently, malondialdehyde (MDA), a lipid peroxidation prod-
uct abundant in AMD retina, has been shown to bind fH
with a strong selective preference for fH402Y, provoking the
suggestion that failure to recruit fH402H to sites of photo-
oxidation damage causes local complement dysregulation
and pathology in AMD [44]. The recent demonstration that
the CFHR1*A allotype, which is risk for AMD, is in strong
LD with CFH402H adds an additional possibility – that the
strong association of AMD risk with the H1 haplotype is
functionally unrelated to the CFH402 polymorphism [16].
The complotype
Together, the inherited repertoire of common polymor-
phisms in genes encoding complement proteins and reg-
ulators affects the delicate balance between activation and
regulation and sets an individual’s intrinsic complement
activity; this repertoire can be referred to as the complo-
type. This term was originally coined to describe haplotypic
combinations of genetic variants of the MHC-linked com-
plement genes [45], but here it is used in the broader
context of the whole complement system. The data dis-cussed so far show that inheritance of more active variants
of AP components (C3, fB) or less active variants of reg-
ulators (fH, fI, MCP) swings the balance in favour of AP
activation and inflammation, whereas inheritance of less
active components and more active regulators dictates less
AP activation and inflammation. Table 1 illustrates theo-
retical values for different combinations of alleles in the
Caucasian population based on individual allele frequen-
cies. We predict that those combinations leading to a more
active complement system put an individual at risk for
inflammation, whereas those combinations at the other
end of the scale are risk for infection.
An additional dimension is provided by inherited vari-
ability in the expression levels of AP proteins. Thus, func-
tional and expression level differences in AP proteins
collude to set AP activating capacity, influencing suscepti-
bility to diseases involving complement. Each of these
disease-associated variants is common in the population
and, individually, their effect is small. Indeed, genetic
studies in AMD and aHUS show that multiple hits, poly-
morphisms and mutations, in AP components are needed
to cause pathology. Penetrance of aHUS in carriers of a
disease-associated AP protein mutation is approximately
50%, but increases considerably if the individual also
carries one or more additional disease-associated mutation
or risk polymorphisms altering function or expression of
another AP protein [24,27]. Whether a variant is risk or
protective depends on the underlying disease trigger and
mechanisms leading to pathology.
So far, this review has focused on three prototypical
diseases of complement dysregulation, AMD, DDD and
aHUS; however, many other diseases are also influenced
by these same polymorphic variants; for example, fH402H is
risk for myocardial infarction and cardiovascular disease
[46], fB32Q is risk for some infections and disproportion-
ately represented in multiple sclerosis and type I diabetes
[47–49], whereas C3102G is risk for not only DDD [50], but
also renal allograft rejection [51], IgA nephropathy [52]
and systemic vasculitis [53].
The complotype extends beyond the AP
In developing the concept of the complotype, we have
focussed on AP components (C3, fB) and regulators (fH,
fI, MCP, FHR proteins). However, the complotype encom-
passes polymorphisms in other complement proteins that
are associated with disease and probably affect aspects of
complement activity.
Genome-wide association studies (GWAS) in Alzhei-
mer’s Disease (AD) have identified polymorphisms in
two other genes encoding proteins associated with the
complement system, complement receptor 1 (CR1; CD35)
and clusterin, that independently influence risk of devel-
oping AD [54,55]. CR1 promotes fI cleavage of C3b to form
iC3b and C3dg, which are ligands for CR3 and CR2,
respectively; the latter being crucial for efficient B cell
response to antigen [56]. CR1 also plays a major role in
erythrocyte-mediated immune complex clearance [57]. The
associated SNPs (rs6656401 and rs3818361) are intronic
and effects on CR1 activity or expression are unknown. A
recent report describes an AD-linked coding polymorphism
in the CR1 gene (rs4844609; S1610T) suggested to influ-517
Table 1. Combined allele frequency of common polymorphic variants in C3R102G (rs2230199; single allele frequency R/G: 0.8/0.2),
fBR32Q (rs641153; R/Q: 0.765/0.11), and fHV62I (rs800292; V/I: 0.79/0.21) and their expected prevalence in the Spanish population.
Allele Combination % Frequency Prevalence in Caucasians
C3102RR, fB32RR, fH62VV 23.4 4 (i.e., 1 in 4)
C3102RR, fB32RR, fH62VI 12.4 8
C3102GR, fB32RR, fH62VV 11.7 9
C3102RR, fB32RQ, fH62VV 6.7 15
C3102GR, fB32RR, fH62VI 6.2 16
C3102RR, fB32RQ, fH62VI 3.6 28
C3102GR, fB32RQ, fH62VV 3.4 30
C3102GG, fB32RQ, fH62VV 2.1 48
C3102GR, fB32RQ, fH62VI 1.8 56
C3102RR, fB32RR, fH62II 1.7 61
C3102GG, fB32RR, fH62VV 1.5 68
C3102GR, fB32RR, fH62II 0.83 121
C3102GG, fB32RR, fH62VI 0.78 129
C3102RR, fB32QQ, fH62VV 0.48 207
C3102RR, fB32RQ, fH62II 0.48 211
C3102RR, fB32QQ, fH62VI 0.257 389
C3102GR, fB32QQ, fH62VV 0.24 414
C3102GR, fB32RQ, fH62II 0.24 421
C3102GG, fB32RQ, fH62VI 0.22 448
C3102GR, fB32QQ, fH62VI 0.13 778
C3102GG, fB32RR, fH62II 0.10 969
C3102RR, fB32QQ, fH62II 0.034 2928
C3102GG, fB32QQ, fH62VV 0.030 3311
C3102GG, fB32RQ, fH62II 0.030 3368
C3102GR,fB32QQ, fH62II 0.017 5856
C3102GG, fB32QQ, fH62VI 0.016 6227
C3102GG, fB32QQ, fH62II 0.002 46851
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Clusterin is a plasma protein that binds fluid phase C5b–7,
thereby preventing formation of membrane attack complex
(MAC) on cells [8]. Clusterin also binds dead and dying
cells and tissue debris, is abundant in plaques in AD
brains, and increased plasma clusterin is a biomarker
for AD disease severity and clinical progression [59].
Two intronic SNPs in the Clu gene, rs9331888 and
rs1136000, show strongest association with AD; the former
influences the pattern of alternative splicing in the Clu
gene [60], and is associated with low plasma clusterin
levels in AD patients and controls [61].
Several studies have described association of SNPs
(rs10818488, rs2416808) in a region of chromosome 9q
that encompasses genes for TNF receptor-associated factor
(TRAF)1 and complement C5 with risk for rheumatoid
arthritis (RA), [62] and coeliac disease [63]. Both TRAF-1
and C5 are excellent candidate genes for perpetuating
inflammation in RA; however, other evidence implicates
the complement terminal pathway in RA pathogenesis,
including identification of TCC in diseased joints, joint fluid
and plasma of RA patients [64]. Terminal pathway activa-
tion is also implicated in osteoarthritis [65], but no complo-
type studies have been reported; this age-associated,
common chronic inflammatory disease is a prime candidate
for future analysis of the role of the complotype in suscepti-
bility or severity. Other SNPs in C5 have been linked to
renal allograft survival [66]; one of four haplotype blocks
spanning 4 C5 SNPs is associated with decreased graft
function at 1 and 7 years post-transplant. Serum C5 levels518are not different between the haplotypes. Intriguingly, a
nonsynonymous coding SNP (rs1926447; T325I) in the gene
for carboxypeptidase B (CPB), a plasma inhibitor of C5a
activity, is associated with decreased risk of severe RA
[67]; the ‘protective’ CPB variant displays increased
plasma half-life and C5a-inhibiting activity, suggesting
a mechanism for the observed protection. Although SNPs
have been described in each of the other terminal compo-
nents, no firm disease associations have yet been reported.
Intriguingly, heterozygous deficiency of C9, very common
in the Japanese population, has recently been shown to
reduce by 4.7-fold the risk of developing neovascular AMD,
emphasising the importance of the terminal pathway in
this disease [68].
The complotype and infection
Functional studies and links to chronic inflammation
demonstrate that an individual inherits a complotype that
places him/her at a point on a spectrum of complement
activity from high to low. Individuals at the high end of the
complotype spectrum are more prone to chronic inflamma-
tion; at the opposite end of the spectrum, individuals with a
low activity complotype are protected from chronic inflam-
mation, but at the cost of increased susceptibility to infec-
tion. A low activity complotype would thus be a negative
selective pressure; in support of this, those variants
that constitute the less active complotype are much less
prevalent (see theoretical values in Table 1). Indeed, in
sub-Saharan African populations at high risk of death
from infection there is further skewing of the complotype
Review Trends in Immunology October 2012, Vol. 33, No. 10towards a more active complement system [69]. A striking
experiment of nature surrounded the sad fate of 19th
century Dutch immigrants to Surinam; soon after arrival
the community was devastated by typhoid and yellow
fever, wiping out 60% of their number. Descendants of
the survivors showed much higher frequency of the
most active C3 allele, C3102G, compared to the source
Dutch population; evidence that selective pressure from
infection acutely selected this infection-protective C3
variant [70].
Evidence that the complotype directly influences infec-
tion risk has emerged from recent genetic studies. A GWAS
for meningococcal disease has identified risk SNPs in CFH
and CFHR3 [71]. The coding SNP in CFH, (rs1065489;
E936D) has been confirmed in a replication study, with the
D allele being protective. Interestingly, meningococcal
disease incidence differs between ethnic groups and
inversely parallels frequency of the protective allele [72].
The associated SNP in CFHR3 is in LD with rs1065489
and could plausibly be causative. However, a targeted
genotyping approach has revealed a polymorphism in a
putative nuclear-factor (NF)-kB responsive element in
CFH, which probably decreases expression of fH, to be
associated with meningococcal disease [73]. It is notable
that this NF-kB polymorphism, which is protective for
meningococcal disease and in the same haplotype as
rs1065489 (E936D) [23], is also associated with risk for
aHUS [23]. Reduced levels of fH, a disadvantage for cell
surface protection and therefore risk for aHUS, may be
protective for meningococcal disease as fH is ‘hijacked’ for
complement protection by Neisseria meningitidis through
binding a bacterial surface receptor, fHbp [74]. Whether or
not reduced binding of fH is the protective mechanism,
these findings strongly implicate complement control in
setting disease risk. It is likely that the whole complotype
will contribute to risk in meningococcal disease – variation
in host-activating proteins will alter the rate or levels of
C3b opsonisation, and variation in activity or levels of
key host control proteins will not only control opsonisation
rate but also affect sensitivity to lysis and protection
afforded by hijacked fH. A common coding polymorphism
in complement C5, rs17611 (V802I), was recently associ-
ated with unfavourable outcome in bacterial meningitis
(OR, 2.25; 95% CI, 1.33–3.81; P=0.002) in a Dutch prospec-
tive study [75]. The effect of this polymorphism on C5
function is unknown.
Concluding remarks
This review presents evidence that common polymor-
phisms in complement proteins dictate complement activi-
ty in an individual with resultant effects on susceptibility
to inflammatory and infectious diseases. Although initially
focussed on the AP and a small group of diseases driven by
AP dysregulation, the complotype encompasses the entire-
ty of the complement system and the list of diseases
affected by complotype grows steadily as genetic studies
implicate known or novel complement polymorphisms.
Even in these few diseases of AP dysregulation, the differ-
ent patterns of linked polymorphisms highlight the fact
that complement is activated in different ways and at
different sites dictated by the complotype to cause differentpathologies. In some diseases the importance of the com-
plotype is revealed by its effect on disease penetrance in
the presence of a causative mutation.
We predict that analysis of an individual’s complotype
will be widely used, in conjunction with environmental and
other known risk factors, to predict disease risk and course
[16,31–33]. Genetic complotype analyses will provide rele-
vant data, but measurement of polymorphic variants at the
protein level using specific monoclonal antibodies is rapid
and will add data on plasma levels [76]. Measurement of
complement activation products, of proven value in AMD,
will provide additional information, particularly valuable
in acute conditions. Multiplexed complotype assays that
measure all relevant complement analytes will enable
rapid and efficient complotyping of individuals at risk,
and identify those most likely to benefit from interventions
– either modifying other risk factors or directly targeting
complement using agents selected based on the complotype.
These measures will have a major impact on morbidity
and mortality in the many diseases involving complement
dysregulation.
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